<DOC>
	<DOCNO>NCT01327924</DOCNO>
	<brief_summary>This study conduct Europe . The purpose study assess impact daily life child new use growth hormone injection device .</brief_summary>
	<brief_title>Usability Tolerability Norditropin NordiFlex® Injection Device Children Never Previously Treated With Growth Hormone</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Growth hormone ( GH ) treatment naïve subject decide initiate GH treatment prior enrollment study Subjects receive Norditropin NordiFlex® accord SPC Known suspect allergy study product ( ) relate product Child and/or parent unable give consent fill questionnaires The receipt investigational medicinal product within 3 month prior study Suffer lifethreatening disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>